Biosensors Korea

Biosensors Korea is the South Korean subsidiary of Biosensors International Group, a global leader in the development and commercialization of innovative medical devices for interventional cardiology. The company is renowned for its drug-eluting stents (DES) and drug-coated balloons (DCB) that utilize its proprietary immunosuppressive drug, Biolimus A9 (BA9), and advanced biodegradable polymer coatings. Its flagship products, including the BioMatrix and BioFreedom stent families, are designed to optimize clinical outcomes for patients with complex coronary artery disease, particularly those at high risk of bleeding. Since its acquisition by Blue Sail Medical in 2016, Biosensors Korea has continued to play a critical role in providing advanced cardiovascular solutions and clinical support within the South Korean healthcare market.